Double live surgery day at @UroMolinette! ✌️😷 ​2 simultaneous procedures performed: ✅ Kidney surgery connecting with @IrcadFrance ✅ Andrological live surgery ​Pushing the boundaries of urology. 🚀 @paolo_gontero @dottceruti @oderdam @giorgiocalleris @FedericoLavagno @medannot

Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > bit.ly/4kwv1sZ @oderdam

Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > bit.ly/4kwv1sZ @oderdam

oaepublish.com/webinars/mis.… Interested in imaging of #radiorecurrent #prostatecancer? Watch this webinar!

#TOP24 TURIN ONCOLOGY PROSTATE CANCER MASTERCLASS. FOR WHO IS INTERESTED IN ADVANCING KNOWLEDGE AND SKILLS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER. 🗓️ 13/12 📍Turin, IT 📲 lnkd.in/gzBucbck @paolo_gontero @UroMolinette @oderdam @GMarra_MD @peppinoiorio

Happy to speak about #laparoscopic #inguinal #lymphadenectomy!

Grande partecipazione del pubblico ieri a Bari per NOW or NEVER – Il ruolo dell’#urologo nel trattamento multimodale del #CarcinomaProstatico, tra #Chirurgia e nuove terapie #Ormonali. Responsabili Scientifici Proff. A. Briganti @Albert0Briganti e N. Suardi @urosuardi. Docenti: M. Oderda, G. Procopio, M. Scarcia, G. Simone. @oderdam @g_procopio_

🧬 Exciting new study shows how Prolaris genomic testing can help men with intermediate-risk #ProstateCancer make better treatment decisions! 📊 Patients recommended for Active Surveillance (AS) by Prolaris were 2x more likely to choose AS and 1.5x more likely to stay on it for 3 years. 🕒 #PrecisionMedicine #CancerResearch #MensHealth #Prolaris #Urology

Clincal and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer by Philip Sutera et al Full article: europeanurology.com/article/… #MedTwitter #UroSoMe #PCa #ProstateCancer

12-13-14/06 2024 ⤵️ 🔎 Laparoscopy training course in Urology 📍 @unito @cittasalute_to ✅ Training simulation & live surgeries. We are ready 🙌 @paolo_gontero Lorenzo Repetto @PaoloDeste37946 @oderdam @Mat_Sibona Marco Allasia @FedericoLavagno CMerzagora MCatalano @SIU_Italia

Molinette Urology Equipe at @ab_medica for #SP #Davinci: @paolo_gontero @frasor86 @oderdam @p_deste

A great honor today for our family at @UroMolinette to have Prof. David Penson @urogeek with us in Turin! 🇮🇹🇺🇸 @paolo_gontero @umbertoricardi Prof.Albera Prof.ssa Cassoni @GMarra_MD @oderdam @frasor86 @MCalandri @cittasalute_to @unito @AmerUrological @VUMChealth

Secondary analysis of TITAN trial shows that half of patients with mHSPC treated with apalutamide who experienced radiographic progression developed it without corresponding PSA progression. Great team @jikei_urology @gehi87 @Keiichiro__Mori @DrShariat sciencedirect.com/science/ar…

Day one with Prof. Jean De La Rosette has gone ✅ Such inspiring talks on BPH minimally invasive treatments 🤩👌 This is our team at @UroMolinette lead by Prof. @paolo_gontero @p_deste @frasor86 @GMarra_MD @Mat_Sibona @ marcoOderda @SIU_urology @cittasalute_to @unito

Read our article @EurUrolOpen on inguinal lymphadenctomy for PeCa 😎 👉🏼 OILND vs VEILND ❌ comparable surgical outcomes ✅ VEILND quicker drain removal and less complications 👉🏼VEILND represents a safe technique authors.elsevier.com/sd/arti… @paolo_gontero @docctoore @oderdam

🆕 Transperineal or Transrectal MRI–targeted Biopsy for #ProstateCancer Detection 🎯 15 🇪🇺 centers - PSM 1301 matched pairs - @KoelisBx 💡ISUP2(3): 51% vs 45%; OR 1.37 (29% vs 23%; OR 1.38) @JulesBordet @sb_uro @ESRUrology @Uroweb sciencedirect.com/science/ar…

🤝🩺 The Société Internationale d’Urologie (SIU) is pleased to support the Università di Torino in helping to disseminate its 3-minute survey to shed light on the current landscape of genetic testing and the use of PARP-inhibitors in different institutions. The answers will be acquired anonymously; the data will not be accessible to third parties and will be used only for scientific purposes. 🥼🧪 The subject of how and when to use genetic tests and PARP-inhibitors in prostate cancer has become one of the hot topics in urology. Not all the institutions and countries are prepared for the widespread use of genetic testing (somatic and/or germline) and not all have access to PARP-inhibitors in their routine clinical practice. 🔎 The insights gathered from this survey will play a crucial role in identifying gaps in current practices to help improve patient care and outcomes in prostate cancer management. Answer the survey today! bit.ly/4c7ZKIC *By answering the questions, you consent to the use of the data for scientific purposes. Thank you for participating! #UroSoMe @unito @paolo_gontero @oderdam @StavrosGravas

Robot-assisted PSMA-radioguided surgery to assess surgical margins and nodal metastases in #ProstateCancer patients: Report on three cases using an intraoperative PET-CT specimen imager. #BeyondTheAbstract with @oderdam @cittasalute_to > bit.ly/3IzYnF2 @urogoldjournal

@oderdam on #microwaves at #TOP23 🇮🇹- #highlyprecise-3D fusion : how focal can we go? @FocalSociety

A packed “Aula Lenti” for a terrific #TOP23 kick-off!! @paolo_gontero @oderdam @FedericoLavagno @UroMolinette @umbertoricardi @MassimoDiMaio75 #prostatecancer #TOPMasterclass Turin 🇮🇹